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Abstract  
 Frailty describes a medical syndrome that confers increased vulnerability to disproportionate changes in 
health status following minor stressors. With loss of homeostatic reserve in multiple physiological systems, 
frailty conveys an increased risk of adverse health outcomes. Despite the lack of a clear universal definition, the 
utilisation of two landmark operational models has allowed a rapid expansion in frailty-centred research. 
 The pathophysiology of frailty is yet to be elucidated in the literature, but a critical role for a 
heightened inflammatory state is hypothesised. Raised levels of pro-inflammatory cytokines are associated with 
frailty, with emerging evidence relating their biochemical action with development of the frailty phenotype.  
Dysregulation of both the innate and adaptive immune system are key components of the frailty syndrome. 
Remodelling of the T cell compartment and upregulated inflammatory pathways are theorised to propagate the 
heightened inflammatory state critical in the frailty syndrome.  Increased neutrophil counts, in conjunction with 
ineffective neutrophil migration associated with age, is theorised to produce tissue damage and secondary 
inflammation conducive of the inflammatory picture in frailty.  
 Beyond the gold standard of the comprehensive geriatric assessment, management of frailty is a fast-
evolving area of research.  Exercise interventions have shown promising results, improving functional ability 
and showing beneficial immunomodulation. Vitamin D supplementation, with proposed anti-inflammatory 
effects, nutritional support and pharmacological treatments all provide promising areas for future therapeutic 
intervention.  
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Frailty and the Frail Immune System  
 Frailty is a syndrome characterised by the loss 
of homeostatic reserve in multiple physiological systems.  
It is a serious issue for an increasingly elderly population 
that is associated with increased vulnerability to 
dramatic health changes in response to often minor 
stressor events (1). Described as the most problematic 
consequence of population ageing (2), frailty conveys an 
increased risk of adverse outcomes, including falls, 
disability and mortality. The resultant burden on both 
health and social care systems globally is only set to 
increase in an internationally ageing population (3, 4). 
Now recognised as a clinical syndrome disparate from 
disability and comorbidity (5), the importance of 
identifying and introducing effective management for 
patients with frailty is becoming increasingly evident.  
 
Defining Frailty  
 The term “frailty” has been used previously to 
describe a whole host of conditions, ranging from 
general debility, bone weakness to cognitive impairment 
(6, 7). However, over the last 20 years, frailty as a 
concept has evolved to be defined as a distinct clinical 
syndrome, widely recognised as a vital diagnosis due to 
its association with poorer clinical outcomes and 
increased health care utilisation. Despite this, there is 
still no universal consensus for the classification of frailty 
as a syndrome. Currently, there are two widely accepted 
operational definitions: the frailty phenotype model and 
the frailty index model, compared in Table 1.  
  The phenotype model, more widely utilised in 
research(8), was pioneered by Fried(9). It states that 
frailty can be thought of as a clinical phenotype 
incorporating five features: shrinking (unintentional 
weight loss), poor endurance and energy (self-reported 
exhaustion), low physical activity level (low energy 
expenditure), slowness (slow gait speed) and weakness 
(weak grip strength)(9). Individuals with three or more of 
these features were classified as frail, one or two 
features as pre-frail. Frailty classified in this way was 
shown to correlate with an increased risk of adverse 
outcomes, including falls, mobility and function, 
hospitalisation and death (9). This association was shown 
to hold true in different and more diverse cohorts such 
as a Chinese cohort (10).  
 The frailty index model was pioneered by 
Rockwood and describes frailty as the cumulative effect 
of individual deficits (11). Patients with more deficits were 
more likely to be frail (11) and were at an increased risk 
of adverse outcomes including mortality (12, 13). Deficits 
were classified as 92 variables, originally identified to 
classify health status in the elderly (14). These variables 
The Frailty Phenotype Model Fried (9) The Frailty Index Model Rockwood (14) 
3/5 of the following: 
 Weight loss 
 Self-reported Exhaustion 
 Low physical Activity 
 Slowness 
 Weakness 
Deficit accumulation of >0.2 of total assessed deficits 
(minimum 30) 
Deficits can include any variable that fulfils the fol-
lowing criteria: 
 Associated with adverse health outcomes 
 Increased in prevalence with age 
 Prevalence ≥ 1% (but not saturated) in old age 
Table 1 – The Frailty Phenotype and Frailty Index operational models of the frailty syndrome.  
With the lack of a single unifying definition, these two operational models provide the definitions of frailty 
used in research and clinical practice. The frailty phenotype model identifies an individual as frail by the 
presence of three of the five symptoms shown above. An individual is classed as pre-frail if they exhibit 
one or two of the symptoms. The frailty index model classifies an individual as frail if their number of 
deficits, as a proportion of the total deficits assessed, is greater than 0.2. Deficits can include any variable 
that is associated with ill health, increases in prevalence with age but does not saturate (≥1%) at old age.  
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include symptoms and signs, functional impairments and 
laboratory abnormalities covering a wide range of 
domains such as social, psychological and medical. The 
frailty index itself is calculated as the presence (score of 
1) or absence (score of 0) of each variable as a 
proportion of the total. An index above 0.2 is classified 
as frail. At an index of 0.65, the deficit accumulation is 
not sustainable with life (15). This model of frailty 
produces a gradation between frailty and good health. It 
recognises that frailty is not just a phenomenon that is 
present or absent, but usually presents as a gradual 
decline into increasing frailty.  The frailty index is seen 
as mathematically attractive, with a distribution similar 
to that seen in systems with in-built redundancy (2). This 
supports the theory of an accumulation of deficits 
leading to reduced homeostatic reserve, resulting in the 
vulnerability which is fundamental to the frailty 
syndrome (2). Rockwood‟s theory has since been refined 
to a more manageable 30 variables, without losing 
validity in different data sets (16).  
 Despite the two vastly different approaches to 
characterising frailty,  both approaches show statistical 
convergence(17). Although each model has their 
advantages; the Frailty index can identify risk of adverse 
outcomes from intermediate frailty more specifically and 
lead to more targeted treatments (17).  The two models 
are distinct but complimentary, with their combined/
sequential use encouraged (18). 
 Frailty, co-morbidity and disability are three 
inter-related clinical entities, which only recently were 
proven to be distinct. Recent research has shown that 
there is consistently a population of frail individuals 
without co-morbidities or disability (5, 19, 20). Despite this, 
the conditions overlap extensively, as a result of causal 
relationships between the three. Frailty often precedes 
disability (21), whilst disability and co-morbidity can 
contribute to the development of frailty (5).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
 Reports on the prevalence of frailty vary from 
study to study due to a lack of a universal, corroborated 
definition of frailty. A systematic review of 21 studies 
yielded a weighted average prevalence of 10.7% in 
community dwelling older adults (aged 65 and older) 
(22). However, this review was subject to a wide variation 
in reporting, resulting in huge disparity in prevalence 
estimates between the included primary studies. What 
was clear however, was the close association with age, 
with around a quarter of individuals over the age of 85 
classified as frail (22).  There was also a clear association 
with gender, frailty being more prevalent in women that 
is independent of age (22).  
Pathophysiology  
 Despite continued research efforts, the clear 
pathogenesis of frailty is still yet to be elucidated. 
Principally, the pathogenesis and progression of frailty is 
associated with accelerated accumulation of cellular and 
molecular damage in multiple bodily systems. This 
damage occurs naturally in normal ageing (23), and most 
body systems have in built redundancy (or physiological 
reserve) which can account for decline in age or disease 
(24). However, there is a threshold of damage, beyond 
which impaired body system function becomes evident. 
Frailty manifests in an individual who has crossed the 
threshold of damage in multiple physiological systems 
(25). Importantly, the number of body systems affected, 
rather than the amount of damage in one system, is the 
strongest predictor of frailty (25).  
 The main three systems focused upon in frailty-
centred research are the immune system, endocrine 
system and nervous system (6). However, changes in 
multiple body systems have documented impacts on the 
frailty syndrome including: the renal system (26), the 
cardiovascular system (27, 28), the haematological system 
(28, 29) and the respiratory system (30).  
 There are a number of associated factors that 
potentially contribute to the pathogenesis of frailty, but 
these are sparsely illustrated and without a significant
evidence base in the literature. We can postulate that 
chronic low-level inflammation has a key 
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pathophysiological role (31, 32), as the inflammatory 
markers IL-6, TNFα and CRP, are elevated in frailty (33-
35). There is also a direct association between frailty and 
an increased total white blood cell count at baseline (35), 
a routine clinical indicator for systemic inflammation (36). 
This chronic inflammation has both indirect and direct 
contribution to the pathophysiology of frailty. IL-6 and 
TNFα themselves show association with the loss of 
muscle mass strength in frailty (37). Inflammation has 
detrimental indirect effects on intermediary systems 
including decreased haemoglobin concentrations (38), 
insulin-like Growth Factor (IGF) levels (39) and 
micronutrient concentrations (40).  These effects reduce 
the physiological reserve of the affected bodily systems, 
contributing to the development of frailty. 
 Sarcopenia is the loss of skeletal muscle mass, 
strength and function (41), which occurs age. With 
weakness and slowness comprising a key part of the 
frailty phenotype, sarcopenia and frailty are 
understandably very closely linked. Many even describe 
sarcopenia as „physical frailty‟. However, we can 
hypothesize that sarcopenia is not only a component of 
frailty but it can actively cause or encourage the 
progression of frailty. Sarcopenia itself is associated with 
a chronic low level inflammatory state driven by 
oxidative stress and inflammatory cytokines, with raised 
levels of IL-6, TNFα and CRP, all considered key in the 
condition‟s pathogenesis (42, 43). The development of 
sarcopenia can lead to a cycle of reduced physical 
activity, under nutrition and further inflammation that is 
extremely difficult to break (44, 45). These factors have all 
been implicated in the pathophysiology of frailty 
suggesting a causative role for sarcopenia. The 
endocrine system is also believed to be fundamental in 
the pathogenesis of sarcopenia and consequently frailty. 
The decrease of oestrogen or testosterone in old age (36) 
and reduced levels of IGF-1 in frail individuals (46) can 
result in sarcopenia. The close relationship between 
sarcopenia and frailty has been postulated to extend to 
the molecular level, with the dysregulation of the PI3K-
Akt signalling proposed to play a role in the 
pathophysiology of both processes (47).   
The Frail Immune System  
 The chronic pro-inflammatory state associated 
with frailty (31-35) is accompanied by dysregulation in 
both the adaptive and innate immune systems (32). 
Whether these changes are cause or consequence of 
frailty is the topic of ongoing research and not yet 
elucidated in the literature.  
 As stated above, there is an association 
between frailty and raised levels of IL-6 and TNF-α (33-
35), as part of the heightened inflammatory state 
accompanying the syndrome. These inflammatory 
cytokines play a crucial role in the pathogenesis and 
propagation of the frailty syndrome.  IL-6 can cause 
muscle degradation in a number of ways: directly by 
action of the proteasome (48), through induction of 
insulin resistance (49) resulting in suppression of skeletal 
muscle hypertrophic Akt-mTOR activity (47, 50) and also 
through the induction of 11βHSD1 (51) which synthesises 
the catabolic molecule cortisol (52). These processes are 
evident in human epidemiological studies which have 
shown that higher levels of IL-6 are predictive of both 
sarcopenia (53) and relevant frailty associated adverse 
health outcomes (54). TNFα can directly induce skeletal 
muscle wasting (55). This is especially relevant as TNFα 
levels in the skeletal muscles of frail older adults were 
shown to be elevated when compared to healthy 
younger individuals (56). With regards to the impact of 
anti-inflammatory cytokines, there is a lack of evidence 
regarding an association between human frailty and IL-
10. However, we can hypothesise that the molecule is 
involved in the syndrome‟s pathogenesis and 
maintenance, with murine models of frailty utilising an 
IL-10 knockout model (57).  
 Evidence is emerging that the T cell 
compartment of the adaptive immune system undergoes 
remodelling in frailty syndrome. Age matched female 
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patients who were frail have been shown to have 
significantly more CD8+CD28- and CD8+ T cells than 
non-frail women (58). Furthermore, dysregulation of CD4 
T cells has been shown to be predictive of a frailty-
related phenotype in HIV infected men (59). These 
findings suggest that T cell dysregulation may well be 
associated in the frailty syndrome.  This is reinforced by 
the finding that frail individuals have increased counts of 
T cells expressing chemokine CC receptor 5, 
representing an increase in a pro-inflammatory T-cell 
subset in frail older adults (60) perhaps contributing to 
the chronic inflammation in frailty. Further studies of the 
quantity, character and function of T cells in frail 
individuals are needed. Information regarding B cell 
function in frailty is extremely limited. There is emerging 
evidence that individuals with frailty have an impaired 
response to vaccination, but it is unclear whether this is 
secondary to the previously described T cell 
dysregulation or dysfunction in the B cell itself (32).  
 The innate immune system of frail individuals 
exhibits increased cellular and molecular inflammatory 
markers (32). Increased IL-6 production by peripheral 
blood mononuclear cells (PBMCs) (61, 62) and elevated 
white blood cell count are both associated with  
frailty (35, 63). We can postulate that these factors are 
crucial in the maintenance of the heightened 
inflammatory state seen in frailty. There is also evidence 
to show an upregulation of the CXCL10 gene in the 
monocytes of individuals with frailty (64), as well as 
upregulation of other inflammatory pathway genes (65), 
further potential causes of the heightened inflammatory 
state in frail older adults. An association between 
oxidative stress, cellular senescence and frailty has been 
proposed, following the observation of increased 
expression of hydrogen peroxide-induced clone 5 (a 
protein that responds to oxidative stress and is key in 
cellular senescence) in monocytes of a frail individual 
(32).  
 Systemic neutrophil and monocyte counts have 
been shown to be raised in frailty (63). However, 
neutrophil chemotactic ability declines with age (66, 67) as 
does the ability of neutrophils to phagocytose bacteria 
(68) or produce extracellular traps (69). Neutrophils, 
although crucial in bacterial clearance and tissue repair, 
can cause tissue damage as evidenced by the 
attenuation of muscle injury elicited on leukocyte 
depletion (70-72). Thus, in frailty we can postulate that an 
increased number of neutrophils, migrating inefficiently, 
and with reduced capacity to effectively clear bacteria 
might cause tissue damage and produce systemic 
inflammation (66, 67), potentially providing significant 
input to the heightened inflammatory state and muscle 
damage seen in frailty.  
Management of Frailty  
 According to the British Geriatrics Society, a 
Comprehensive Geriatric Assessment (CGA) reflects the 
gold standard of care for patients with frailty (73). Frail 
patients admitted to hospital who received a CGA were 
more likely to return to their homes, less likely to suffer 
deterioration or death and showed improved cognition 
(74). The key components, first described by Rubenstein 
(75), are: co-ordinated multidisciplinary assessment, 
geriatric medicine expertise, identification of medical, 
physical, social and psychological problems and the 
formation of a care plan (74). The main limitation of the 
CGA is its resource intensive nature which can restrict its 
incorporation into practice. 
 As far as interventions to prevent or reverse 
frailty itself, there is currently limited available research. 
Therefore, to improve our understanding we have also 
considered studies have been conducted in populations 
that, although not explicitly categorised as frail, may 
well have been frail at the time of data collection. 
Exercise interventions of various types have shown 
promising results in the literature. Systematic reviews on 
the topic suggest that exercise may improve functional 
ability and decrease disability (76, 77) in moderately frail 
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individuals, but not in the severely frail (76). In these 
reviews, exercise was defined as activity requiring 
physical effort that is intended to improve or maintain 
fitness (76, 77). The review conducted by Clegg et al (76) 
focused on home-based resistance exercise 
interventions, whereas the review conducted by Theou 
et al (77) encompassed both resistance and 
multicomponent interventions. The effects of resistance 
exercise in particular seem promising in clinical trials, 
reducing physical decline (78) and counteracting the 
weakness associated with physical frailty (79). There is a 
growing body of evidence for the use of exercise to 
reduce the chronic low level inflammation critical in 
frailty (42, 80). Resistance exercise in particular has been 
shown to modulate the immune system in frail older 
adults, reducing TNFα levels in skeletal muscle and 
permitting increased muscle protein synthesis (56). A 
Cochrane review of patients in long-term residential 
care, who are likely to be frail, suggests that physical 
rehabilitation can reduce disability and improve physical 
condition (81). This was supported by a separate meta-
analysis that found that mobility and physical 
functioning was improved with physical exercise therapy 
in an older population with mobility issues (82). However, 
an update of the Cochrane review highlighted the 
difficulty of drawing valid conclusions using meta-
analysis from such varied datasets and interventions but 
did suggest that individual studies have demonstrated 
benefit to health status with physical activity (83). The 
effect of exercise on the quality of life remains 
uncertain, with no conclusive evidence on the subject (76, 
82). High-intensity exercise seems to be the most 
effective when compared to low intensity exercise (79, 82), 
but there was insufficient evidence to make a strong 
recommendation (77).  
 Another potential treatment for frailty is 
nutritional and hormonal support. Caloric and protein 
support as well as Vitamin D replacement are both listed 
in the Frailty Consensus from 2013 (84) as potential 
therapies for physical frailty. Protein supplementation 
has been shown to improve grip strength and reduce 
weight loss (85). Protein supplementation has also been 
shown to improve physical performance in frail elderly 
volunteers (86), especially when combined with resistance 
exercise (87, 88). A reduced Vitamin D level has shown 
strong associations with both prevalent and incident 
physical frailty after adjusting for common confounders 
(89). Vitamin D supplementation can reduce the risk of 
falls (90), improve strength (91) and reduce mortality (92) in 
older patients. However, it is worth noting that there is 
conflicting evidence regarding the benefit of vitamin D 
supplementation, with recent research suggesting that 
high dose supplementation can increase the risk of falls 
in older adults (93). This disparity in the literature on 
vitamin D supplementation may be due to inexpert 
targeting of the treatment and once the mechanism of 
action is better understood, studies may be able to show 
increased benefit. Recent research efforts have explored 
the immunomodulatory effects of vitamin D and its 
potential use in the treatment of inflammatory diseases 
(94-97). The anti-inflammatory effect of vitamin D on 
human immune cells is well documented, with reduced 
production of pro-inflammatory cytokines (98, 99). With 
the effect of vitamin D supplementation on inflammation 
currently being investigated (100), we can hypothesise 
that vitamin D supplementation could produce beneficial 
modulation of the frail immune system. Despite the lack 
of large-scale trials assessing the efficacy of vitamin D 
supplementation at preventing frailty directly, the limited 
evidence for immune modulation in a frail population 
and the conflicting evidence for its use in fall prevention, 
it provides a promising area of research for therapeutic 
intervention.  
 No substantial body of research supports other 
pharmacological treatments for frailty. It has been 
suggested that Angiotensin Converting Enzyme 
inhibitors (ACEi) can improve muscle structure (101) and 
prevent the decline in muscle strength (102). The LACE 
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Trial (103), which is currently ongoing, is set to examine 
whether ACEi can be used to treat sarcopenia. However, 
this has not been examined in frailty or in enough 
details to make recommendations for clinical practice. 
ACEi have also been shown to produce anti-
inflammatory effects in multiple patient groups (104, 105). 
Whether the anti-inflammatory effects of ACEi would 
prove beneficial in reducing the heightened 
inflammatory state present in frailty will need further 
investigation. Testosterone can improve strength, but 
carries with it significant risk of cardiovascular adverse 
events (106). IGF-1 administration affects skeletal muscle 
directly but has no proven effect on muscle strength 
(107). 
 Figure 1 provides a summation of factors that 
have been implicated in the pathogenesis of frailty and 
therapeutic strategies that might improve patient 
outcomes. 
Conclusion  
 Frailty is a medical syndrome with increasing 
importance in global health care. Associated with an 
increased risk of adverse outcomes in older adults, its 
identification and appropriate management is essential 
for effective patient care. Continued research efforts will 
further our knowledge regarding the syndrome‟s 
Figure 1 – The theorised influence of a heightened inflammatory state on the pathogenesis of 
the frailty syndrome.  
The chronic pro-inflammatory state manifest in frailty can lead directly or indirectly to the development of 
frailty and consequently the associated adverse health outcomes (depicted in red). This inflammatory pic-
ture can affect intermediary systems; sarcopenia and the decline of the musculoskeletal system associated 
with frailty pathogenesis. The remodelling of both the innate and adaptive immune systems associated with 
the frailty syndrome plays a key role, but whether this is cause or consequence is yet to be decided. Prom-
ising management options (depicted in blue) are emerging in the literature, providing beneficial immuno-
modulation and improving functional outcomes.  
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complex pathophysiology and potential for curative 
management and therapeutics strategies. The immune 
system is hypothesised to have a key role in the 
pathogenesis of frailty, with significant changes 
observed in the immune systems of individuals with 
frailty. However, whether these changes are cause or 
consequence will be the subject of further research.    
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